# A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer

> **NCT06266143** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Wuhan YZY Biopharma Co., Ltd.** · enrollment: 71 (actual)

## Conditions studied

- Advanced Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Y101D

## Key facts

- **NCT ID:** NCT06266143
- **Lead sponsor:** Wuhan YZY Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-08
- **Primary completion:** 2025-03-21
- **Final completion:** 2025-10-20
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06266143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06266143, "A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06266143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*